Drug Profile
Research programme: eye disorder therapeutics - Sirion Therapeutics
Alternative Names: SIR-1032; SIR-1076; ST-604; ST-701; ST-702Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sirion Therapeutics
- Class Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dry macular degeneration; Eye disorders; Retinal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dry macular degeneration in USA (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Topical)